Observational Study of Need for Thrombolytic Therapy and Incidence of Bacteremia using Taurolidine-Citrate-Heparin, Taurolidine-Citrate and Heparin Catheter Locks in Patients Treated with Hemodialysis

Seminars in Dialysis

Volumn 25, Issue 2, 2012, Pages 233-238

  Solomon, Laurie R ^a   Cheesbrough, John S ^a   Bhargava, Ramya ^a   Mitsides, Nicos ^a   Heap, Michael ^a   Green, Gerwyn ^b   Diggle, Peter ^b  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; CITRIC ACID; DRUG DERIVATIVE; HEPARIN; TAURINE; TAUROLIDINE; THIADIAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; BACTEREMIA; CATHETER INFECTION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; EQUIPMENT; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; INCIDENCE; INDWELLING CATHETER; KAPLAN MEIER METHOD; MALE; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEEDS ASSESSMENT; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; STATISTICAL MODEL; TREATMENT OUTCOME; VASCULAR PATENCY;

ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; BACTEREMIA; CATHETER-RELATED INFECTIONS; CATHETERS, INDWELLING; CITRIC ACID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EQUIPMENT CONTAMINATION; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; NEEDS ASSESSMENT; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK ASSESSMENT; TAURINE; THIADIAZINES; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84858697956     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00951.x     Document Type: Article

References (37)

1. The national dialysis access survey - preliminary results. UK Renal Registry Report. Chapter 6: 94-96, 2005
2. McIntyre CW, Hulme LJ, Taal M, Fluck RJ: Locking of tunnelled hemodialysis catheters with gentamicin and heparin. Kidney Int 66:801-805, 2004
3. Dogra GK, Herson H, Hutchison B, Irish AB, Heath CH, Golledge C, Luxton G, Moody H: Prevention of tunnelled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomised control study. J Am Soc Nephrol 13:2133-2139, 2002
4. Nori US, Manoharan A, Yee J, Besarab A: Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. Am J Kidney Dis 48:596-605, 2006
5. Saxena AK, Panhotra BR, Sundaram DS, Naguib M, Morsy F, Al-Arabi Al-Ghamdi AM: Enhancing the survival of tunnelled hemodialysis catheters using an antibiotic lock in the elderly: a randomised, double-blind clinical trial. Nephrology 11:299-305, 2006
6. Labriola L, Crott R, Jadoul M: Preventing hemodialysis catheter-related bacteremia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. Nephrol Dial Transplant 23:1666-1672, 2008
7. Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M: Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis 47:83-93, 2008
8. Landry DL, Braden GL, Gobeille SL, Haessler SD, Vaidya CK, Sweet SJ: Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol 10:1799-1804, 2010
9. Venditto M, Tezenas du Montcel S, Robert J, Robert J, Trystam D, Dighiero J, Hue D, Bessette C, Deray G, Mercadal L: Effect of catheter-lock solutions on catheter-related infection and inflammatory syndrome in hemodialysis patients: heparin versus citrate 46% versus heparin/gentamicin. Blood Purif 29:268-273, 2010
10. Dixon J, Steele M, Makanjuola D: Does the use of line locks lead to antibiotic resistant organisms as compared with systemic antibiotics alone in the treatment of hemodialysis catheter infections? (abstract) Liverpool: Renal Association, 2009: P119
11. Quarello F, Forneris G: Prevention of hemodialysis catheter-related bloodstream infection using an antimicrobial lock. Blood Purif 20:87-92, 2002
12. Taylor C, Cahill J, Gerrish M, Little J: A new hemodialysis catheter-locking agent reduces infections in hemodialysis patients. J Ren Care 34(3):116-120, 2008
13. Jurewitsch B, Jeejeebhoy KN: Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infections. Clin Nutr 24:462-465, 2005
14. Allon M: Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis 36:1539-1544, 2003
15. Betjes MGH, van Agteren M: Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 19(6):1546-1551, 2004
16. Shah CB, Mittelman MW, Costerton JW, Parenteau S, Pelak M, Arsenault R, Mermel LA: Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 46:1674-1679, 2002
17. Solomon LR, Cheesbrough JS, Ebah L, Al-Sayed T, Heap M, Milband M, Waterhouse D, Mitra S, Curry A, Saxena R, Bhat R, Schulz M, Diggle P: A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Am J Kidney Dis 55:1069-1078, 2010
18. Geron R, Tanchileski O, Kristal B: Catheter lock solution - taurolock for prevention of catheter-related bacteremia in hemodialysis patients. Harefuah 145:881-884, 2006
19. Vanholder R, Canaud B, Fluck R, Jadoul M, Labriola L, Marti-Monros A, Tordoir J, Van Biesen W: Diagnosis, prevention and treatment of hemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). NDT Plus 3:234-246, 2010
20. Fluck R, Kumwenda M: Renal Association clinical practice guidelines, vascular access for hemodialysis. Guideline 5.4., 2010
21. Hemmelgarn BR, Moist LM, Lok CE, Tonelli M, Manns BJ, Holden RM, et al.: Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activaror. N Engl J Med 364:303-312, 2011
22. Yevzlin AS, Sanchez RJ, Hiatt JG, Washington MH, Wakeen M, Hofmann RM, Becker YT: Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Semin Dial 20:351-354, 2007
23. Weijmer MC, Debets-Ossenkopp YJ, Van de Vondervoort FJ, ter Wee PM: Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 17:2189-2195, 2002
24. Moran JE, Ash S: Locking solutions for hemodialysis catheters; heparin and citrate-a position paper by ASDIN. Semin Dial 21:490-492, 2008
25. Maya ID, Smith T, Allon M: Does the heparin lock concentration affect hemodialysis catheter patency? Clin J Am Soc Nephrol 5:1458-1462, 2010
26. Shanks RM, Sargent JL, Martinez RM, Graber ML, O'Toole GA: Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 21:2247-2255, 2006
27. Droste JC, Jeraj HA, MacDonald A, Farrington K: Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 51:849-855, 2003
28. Regamey C, Schaberg D, Kirby WM: Inhibitory effect of heparin on gentamicin concentrations in blood. Antimicrob Agents Chemother 1:329-332, 1972
29. Weijmer MC, Van den Dorpel MA, Van de Ven PJG, ter Wee PM, Van Geelen JACA, Groeneveld JO, Van Jaarsveld BC, Koopmans MG, le Poole CY, Schrander-Van der Meer AM, Siegert CEH, Stas KJF: Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 16:2769-2777, 2005
30. Polaschegg HD, Sodemann K: Safety of concentrated trisodium citrate catheter locks. Nephrol Dial Transplant 23:4075-4076, 2008
31. US Food and Drug Administration: FDA issues warning on tricitrasol dialysis catheter anticoagulant. FDA Talk paper TOO-16 14 April 2000.
32. Lok CE, Appleton D, Bhola C, Khoo B, Richardson RM: Trisodium citrate 4%-an alternative to heparin capping of Hemodialysis catheters. Nephrol Dial Transplant 22:477-483, 2007
33. Grudzinski L, Quinan P, Kwok S, Pierratos A: Sodium citrate 4% locking solution for central venous dialysis catheters-an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant 22:471-476, 2007
34. MacRae JM, Dojcinovic I, Djurdjev O, Jung B, Shalansky S, Levin A, Kiaii M: Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clin J Am Soc Nephrol 3:369-374, 2008
35. Power A, Duncan N, Singh SK, Brown W, Dalby E, Edwards C, Lynch K, Prout V, Cairns T, Griffith M, McLean A, Palmer A, Taube D: Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single center randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters. Am J Kidney Dis 53:1034-1041, 2009
36. Maki DG, Ash SR, Winger RK, Lavin P: A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomised trial. Crit Care Med 39:613-620, 2011
37. Jain G, Allon M, Saddekni S, Barker J-F, Maya ID: Does heparin coating improve patency or reduce infection of tunneled dialysis catheters? Clin J Am Soc Nephrol 4:1787-1790, 2009